Securian Asset Management Inc. Reduces Stock Position in HCA Healthcare, Inc. $HCA

Securian Asset Management Inc. lessened its position in HCA Healthcare, Inc. (NYSE:HCA) by 45.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 4,344 shares of the company’s stock after selling 3,611 shares during the period. Securian Asset Management Inc.’s holdings in HCA Healthcare were worth $2,028,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Pure Financial Advisors LLC lifted its holdings in shares of HCA Healthcare by 14.2% in the 4th quarter. Pure Financial Advisors LLC now owns 726 shares of the company’s stock worth $339,000 after acquiring an additional 90 shares during the last quarter. Income Insurance Ltd bought a new stake in shares of HCA Healthcare in the 4th quarter worth about $249,000. D Orazio & Associates Inc. lifted its holdings in shares of HCA Healthcare by 12.6% in the 4th quarter. D Orazio & Associates Inc. now owns 589 shares of the company’s stock worth $275,000 after acquiring an additional 66 shares during the last quarter. Plato Investment Management Ltd lifted its holdings in shares of HCA Healthcare by 0.6% in the 4th quarter. Plato Investment Management Ltd now owns 3,908 shares of the company’s stock worth $1,833,000 after acquiring an additional 22 shares during the last quarter. Finally, JSF Financial LLC bought a new stake in HCA Healthcare during the 4th quarter valued at about $1,227,000. Institutional investors own 62.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on HCA shares. UBS Group lifted their price objective on shares of HCA Healthcare from $598.00 to $635.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Wall Street Zen lowered shares of HCA Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Sanford C. Bernstein decreased their price objective on shares of HCA Healthcare from $541.00 to $503.00 and set a “market perform” rating for the company in a report on Tuesday, April 28th. Mizuho lifted their price objective on shares of HCA Healthcare from $540.00 to $585.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, Truist Financial cut their target price on shares of HCA Healthcare from $546.00 to $535.00 and set a “buy” rating on the stock in a research report on Monday, April 27th. Sixteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $517.82.

Insider Transactions at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 1,694 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $533.37, for a total value of $903,528.78. Following the transaction, the executive vice president owned 8,853 shares of the company’s stock, valued at $4,721,924.61. The trade was a 16.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Christopher F. Wyatt sold 4,000 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total transaction of $2,020,000.00. Following the completion of the transaction, the senior vice president directly owned 44,379 shares in the company, valued at approximately $22,411,395. The trade was a 8.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 13,714 shares of company stock valued at $7,050,460 in the last 90 days. Insiders own 1.50% of the company’s stock.

HCA Healthcare Stock Performance

NYSE HCA opened at $426.58 on Tuesday. The company has a market capitalization of $94.63 billion, a price-to-earnings ratio of 14.67, a price-to-earnings-growth ratio of 1.38 and a beta of 1.18. The company’s 50-day simple moving average is $487.44 and its two-hundred day simple moving average is $486.55. HCA Healthcare, Inc. has a one year low of $330.00 and a one year high of $556.52.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, April 24th. The company reported $7.15 EPS for the quarter, missing analysts’ consensus estimates of $7.19 by ($0.04). HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The business had revenue of $19.11 billion for the quarter, compared to analysts’ expectations of $19.09 billion. During the same period last year, the business posted $6.45 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Equities analysts expect that HCA Healthcare, Inc. will post 30.07 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 16th will be given a $0.78 dividend. The ex-dividend date of this dividend is Tuesday, June 16th. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare’s payout ratio is presently 10.73%.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.